Skip to main content
. 2014 Mar 7;21(7):1119–1131. doi: 10.1038/cdd.2014.31

Figure 2.

Figure 2

Clinically relevant doses of temozolomide cause a significant increase in the GSC pool in vitro. Such an increase is originated from either the amplification of the GSC population or the conversion of non-GSCs into GSCs. FACS analysis of sorted and unsorted glioma cells treated with either DMSO or 50 μM of TMZ for 8 days. (a) The increase in the GSC population happens over time and in a time-dependent manner in all tested cell lines (figure depicting U251 cell line and GBM43-xenografted specimen). (b) This finding holds true for both unsorted and sorted (DN, CD15+, and DP) U251 populations. We observed a maximum increase in the GSC population 8 days post-initial TMZ therapy. There are both an amplification of GSCs and a conversion of DN non-GSCs into single-positive or double-positive GSCs. DN: FACS-sorted non-GSCs expressing double-negative markers (CD133−CD15−), CD15+: sorted GSCs expressing only the CD15 marker, DP: sorted GSCs expressing double-positive markers (CD133+CD15+). Error bars denote S.E.M. P: ns (P>0.05), *P<0.05, **P<0.01, ***P<0.001, one-way analysis of variance